Drug intelligence / Profile preview

emactuzumab + paclitaxel

Development stage: Unknown
Lead developer: SynOx Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

emactuzumab + paclitaxel is an investigational combination of emactuzumab, a monoclonal antibody targeting colony-stimulating factor-1 receptor (CSF1R), with paclitaxel, a microtubule-stabilizing chemotherapeutic agent. Emactuzumab depletes tumor-associated macrophages (TAMs) in the tumor microenvironment, potentially enhancing anti-tumor immunity. Paclitaxel disrupts cell division by stabilizing microtubules. This combination was evaluated in Phase 1 trials in patients with advanced or metastatic solid tumors, including breast and ovarian cancer, mainly to assess safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy.

Other names: emactuzumab + paclitaxelRO5509554 + paclitaxel

Targets

CSF1R (Macrophage colony-stimulating factor receptor)Microtubule

Beyond the preview

Go deeper on emactuzumab + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on emactuzumab + paclitaxel.

Explore the full profile